Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BRN028
MIFTS: 74

Brain Cancer

Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Brain Cancer

About this section

MalaCards integrated aliases for Brain Cancer:

Name: Brain Cancer 12 54 15
Malignant Neoplasm of Brain 29 71 32
Adult Brain Tumor 12 54 71
Brain Neoplasms 74 43 71
Primary Malignant Neoplasm of Brain 12 71
Neoplasm of Brain 12 6
Brain Neoplasm 12 17
Brain Tumors 54 42
Malignant Primary Brain Neoplasm 12
Adult Malignant Brain Neoplasm 12
Malignant Tumor of Adult Brain 12
Malignant Primary Brain Tumors 54
Malignant Primary Brain Tumor 12
Malignant Tumor of Brain 12
Malignant Brain Tumour 12
Primary Brain Neoplasm 12
Brain Neoplasm, Adult 12
Primary Brain Tumors 15
Brain Tumor, Primary 71
Primary Brain Tumor 12
Brain Tumor Primary 54
Tumor of the Brain 12
Brain Tumor, Adult 52
Bt - Brain Tumour 12
Cancer, Brain 39

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Mental diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1319
ICD9CM 34 191 239.6
MeSH 43 D001932
ICD10 32 C71 C71.9
UMLS 71 C0006118 C0153633 C0220624 more
Sources

Summaries for Brain Cancer

About this section
MedlinePlus : 42 A brain tumor is a growth of abnormal cells in the tissues of the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Some are primary brain tumors, which start in the brain. Others are metastatic, and they start somewhere else in the body and move to the brain. Brain tumors can cause many symptoms. Some of the most common are Headaches, often in the morning Nausea and vomiting Changes in your ability to talk, hear, or see Problems with balance or walking Problems with thinking or memory Feeling weak or sleepy Changes in your mood or behavior Seizures Doctors diagnose brain tumors by doing a neurologic exam and tests including an MRI, CT scan, and biopsy. Treatment options include watchful waiting, surgery, radiation therapy, chemotherapy, and targeted therapy. Targeted therapy uses drugs or other substances that attack cancer cells with less harm to normal cells. Many people get a combination of treatments. NIH: National Cancer Institute

MalaCards based summary : Brain Cancer, also known as malignant neoplasm of brain, is related to brain stem cancer and li-fraumeni syndrome, and has symptoms including seizures, tremor and back pain. An important gene associated with Brain Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are TGF-Beta Pathway and Cytokine Signaling in Immune system. The drugs Tramadol and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and lung, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.

Wikipedia : 74 A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors:... more...

Sources

Related Diseases for Brain Cancer

About this section

Diseases related to Brain Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1148)
# Related Disease Score Top Affiliating Genes
1 brain stem cancer 34.2 TP53 OLIG2 MGMT IDH1 EGFR
2 li-fraumeni syndrome 34.2 TP53 SMARCB1 PTEN IDH1 EGFR
3 medulloblastoma 33.9 TP53 SMARCB1 PTPN11 PTEN PIK3CA NRAS
4 brain glioma 33.7 TP53 PTEN NES MGMT IDH2 IDH1
5 neurofibromatosis, type ii 33.4 TP53 PTEN EGFR EGF
6 cowden syndrome 33.4 TP53 PTEN PIK3CA EGFR
7 infratentorial cancer 33.3 TP53 SMARCB1 PTEN OLIG2 NES MIR25
8 supratentorial cancer 33.2 TP53 SMARCB1 OLIG2 NES MGMT IDH1
9 gliomatosis cerebri 33.1 TP53 PTEN NES IDH1 EGFR BRAF
10 lung cancer 33.1 TP53 PTEN PIK3CA NRAS MIR25 MIR142
11 spinal cancer 32.9 TP53 SMARCB1 IDH1
12 glioblastoma multiforme 32.8 TP53 PTEN PIK3CA NRAS NES MGMT
13 atypical teratoid rhabdoid tumor 32.8 TP53 SMARCB1 MIR142 ALK
14 glioma 32.5 TP53 PTEN PIK3CA MIR25 IDH2 IDH1
15 glial tumor 32.3 PTEN OLIG2 IDH1
16 giant cell glioblastoma 32.3 TP53 SMARCB1 PTEN OLIG2 NES MGMT
17 cerebral ventricle cancer 32.1 TP53 SMARCB1 OLIG2 NES MGMT IDH1
18 meningioma, familial 31.9 TP53 SMARCB1 PTPN11 PTEN PIK3CA MGMT
19 oligodendroglioma 31.9 TP53 PTEN OLIG2 MGMT IDH2 IDH1
20 gemistocytic astrocytoma 31.9 TP53 PTEN MGMT IDH2 IDH1
21 central nervous system benign neoplasm 31.8 TP53 PTEN OLIG2 IDH1
22 supratentorial primitive neuroectodermal tumor 31.8 SMARCB1 OLIG2 IDH1
23 melanoma 31.8 TP53 PTEN PIK3CA NRAS IDH1 EGFR
24 malignant glioma 31.8 TP53 PTEN MGMT EGFR EGF
25 pleomorphic xanthoastrocytoma 31.8 TP53 SMARCB1 MGMT IDH1 BRAF
26 colorectal cancer 31.8 TP53 PTEN PIK3CA NRAS MIR25 MIR142
27 frontal lobe neoplasm 31.8 TP53 MGMT IDH1 EGFR
28 central nervous system cancer 31.8 TP53 SMARCB1 PTEN OLIG2 NES MIR142
29 grade iii astrocytoma 31.7 TP53 PTEN OLIG2 NES MGMT IDH2
30 neuroblastoma 31.7 TP53 PTPN11 PTEN PIK3CA NRAS NES
31 astroblastoma 31.7 NES IDH1 BRAF
32 myeloma, multiple 31.6 TP53 PTPN11 PTEN NRAS MIR25 MIR142
33 pilomyxoid astrocytoma 31.6 IDH2 IDH1 BRAF
34 brain stem glioma 31.5 TP53 PTEN PIK3CA OLIG2 NES MGMT
35 endometrial cancer 31.5 TP53 PTPN11 PTEN PIK3CA NRAS MIR142
36 small cell carcinoma 31.5 TP53 PTEN EGFR ALK
37 carcinosarcoma 31.5 TP53 PTEN PIK3CA EGFR
38 transitional cell carcinoma 31.4 TP53 PTEN PIK3CA EPHB2 EGFR BRAF
39 fibrillary astrocytoma 31.4 TP53 PTEN OLIG2 MGMT IDH2 IDH1
40 intrahepatic cholangiocarcinoma 31.4 TP53 PTEN IDH2 IDH1 EGFR
41 myelodysplastic syndrome 31.4 TP53 PTPN11 PTEN NRAS MGMT IDH2
42 glioma susceptibility 1 31.4 TP53 PTPN11 PTEN PIK3CA OLIG2 NRAS
43 ganglioglioma 31.4 TP53 SMARCB1 NES IDH1 BRAF
44 cholangiocarcinoma 31.3 TP53 PIK3CA IDH2 IDH1 EGFR BRAF
45 renal cell carcinoma, nonpapillary 31.3 TP53 PTEN PIK3CA NRAS MIR142 EGFR
46 lung cancer susceptibility 3 31.3 TP53 PTEN PIK3CA NRAS MIR142 MGMT
47 gliosarcoma 31.3 TP53 PTEN OLIG2 NES MGMT IDH2
48 mixed glioma 31.3 TP53 PTEN OLIG2 NES MGMT IDH2
49 pancreatic cancer 31.3 TP53 PTEN PIK3CA NES MIR25 MIR142
50 spinal disease 31.3 TP53 PTEN OLIG2 NES MIR142 MGMT

Comorbidity relations with Brain Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Brain Edema
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Hypertension, Essential
Obstructive Hydrocephalus Schizophreniform Disorder

Graphical network of the top 20 diseases related to Brain Cancer:



Diseases related to Brain Cancer
Sources

Symptoms & Phenotypes for Brain Cancer

About this section

UMLS symptoms related to Brain Cancer:


seizures, tremor, back pain, headache, syncope, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Brain Cancer according to GeneCards Suite gene sharing:

26 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.16 PIK3CA
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 10.16 NES
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-147 10.16 NES
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-152 10.16 PTEN
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 10.16 PIK3CA
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.16 PIK3CA
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 10.16 PIK3CA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.16 BIRC6 PIK3CA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-186 10.16 NES
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.16 PIK3CA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.16 BIRC6 PIK3CA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.16 BIRC6 PIK3CA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.16 PIK3CA
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.16 PIK3CA
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-69 10.16 IDH2
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-74 10.16 BIRC6
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.16 NES
18 Decreased viability GR00055-A-1 9.96 EGFR PIK3CA
19 Decreased viability GR00055-A-2 9.96 EGFR PIK3CA
20 Decreased viability GR00221-A-1 9.96 ALK EGFR NRAS PIK3CA SMARCB1
21 Decreased viability GR00221-A-2 9.96 PIK3CA SMARCB1
22 Decreased viability GR00221-A-3 9.96 NRAS SMARCB1
23 Decreased viability GR00221-A-4 9.96 ALK EGFR PIK3CA
24 Decreased viability GR00249-S 9.96 ALK SMARCB1
25 Decreased viability GR00381-A-1 9.96 SMARCB1
26 Decreased viability GR00402-S-2 9.96 PIK3CA
27 Decreased cell migration GR00055-A-1 9.65 ALK EPHB2
28 Decreased cell migration GR00055-A-3 9.65 BRAF EGFR PIK3CA
29 Reduced mammosphere formation GR00396-S 9.17 BRAF EGFR IDH2 NRAS PTEN PTPN11

MGI Mouse Phenotypes related to Brain Cancer:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.39 ALK BIRC6 BRAF EGF EGFR EPHB2
2 endocrine/exocrine gland MP:0005379 10.34 ALK BIRC6 BRAF EGF EGFR EPHB2
3 cellular MP:0005384 10.32 BIRC6 BRAF EGFR EPHB2 NRAS OLIG2
4 mortality/aging MP:0010768 10.32 ALK BIRC6 BRAF EGFR EPHB2 IDH1
5 cardiovascular system MP:0005385 10.29 BIRC6 BRAF EGFR IDH2 NRAS PIK3CA
6 immune system MP:0005387 10.28 BIRC6 BRAF EGF EGFR IDH1 NRAS
7 integument MP:0010771 10.26 ALK BIRC6 BRAF EGF EGFR NRAS
8 digestive/alimentary MP:0005381 10.23 BRAF EGF EGFR EPHB2 NRAS PTEN
9 embryo MP:0005380 10.22 BIRC6 BRAF EGFR NRAS PIK3CA PTEN
10 neoplasm MP:0002006 10.21 ALK BRAF EGFR IDH2 MGMT NRAS
11 nervous system MP:0003631 10.18 ALK BIRC6 BRAF EGFR EPHB2 MGMT
12 adipose tissue MP:0005375 10.14 BRAF EGFR OLIG2 PIK3CA PTEN PTPN11
13 liver/biliary system MP:0005370 10.1 BIRC6 BRAF EGFR NRAS PTEN PTPN11
14 muscle MP:0005369 10.06 BRAF EGFR OLIG2 PIK3CA PTEN PTPN11
15 limbs/digits/tail MP:0005371 10.05 BRAF EGFR IDH2 NRAS PTEN PTPN11
16 reproductive system MP:0005389 9.96 ALK BRAF EGF EGFR EPHB2 PIK3CA
17 no phenotypic analysis MP:0003012 9.91 EGFR MGMT NRAS OLIG2 PIK3CA PTPN11
18 pigmentation MP:0001186 9.87 ALK BRAF EGFR NRAS PTEN PTPN11
19 respiratory system MP:0005388 9.81 ALK BRAF EGFR IDH1 MGMT OLIG2
20 skeleton MP:0005390 9.73 ALK BRAF EGFR IDH1 IDH2 NRAS
21 vision/eye MP:0005391 9.4 ALK BRAF EGF EGFR EPHB2 NRAS
Sources

Drugs & Therapeutics for Brain Cancer

About this section

Drugs for Brain Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 640)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
2
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
5
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
6
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
7
Phenylephrine Approved Phase 4 59-42-7 6041
8
Pseudoephedrine Approved Phase 4 90-82-4 7028
9
Ephedrine Approved Phase 4 299-42-3 9294
10
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
11
Morphine Approved, Investigational Phase 4 57-27-2 5288826
12
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
13
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
14
Cabergoline Approved Phase 4 81409-90-7 54746
15
Labetalol Approved Phase 4 36894-69-6 3869
16
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
17
Hydralazine Approved Phase 4 86-54-4 3637
18
Clevidipine Approved, Investigational Phase 4 167221-71-8
19
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
20
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
21
Memantine Approved, Investigational Phase 4 19982-08-2 4054
22
Donepezil Approved Phase 4 120014-06-4 3152
23
Propranolol Approved, Investigational Phase 4 525-66-6 4946
24
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
25
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
26
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
27
Amitriptyline Approved Phase 4 50-48-6 2160
28
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
29
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
30
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
31
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
32
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
33
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
34
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
35 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
36
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
37
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
38
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
39
Racepinephrine Approved Phase 4 329-65-7 838
40
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
41
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
42
Conivaptan Approved, Investigational Phase 4 210101-16-9 151171
43
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
44
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
45 calcium channel blockers Phase 4
46 Central Nervous System Stimulants Phase 4
47 Dopamine Agents Phase 4
48 Cytochrome P-450 Enzyme Inhibitors Phase 4
49 Cytochrome P-450 CYP3A Inhibitors Phase 4
50 Antiparkinson Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1778)
# Name Status NCT ID Phase Drugs
1 Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery Unknown status NCT02964416 Phase 4 Injection Tramadol
2 GCSF Plus Plerixafor as First-line Treatment for Autologous Stem Cells Harvest in Children With Malignant Diseases in Need for High-dose Chemotherapy With Stem Cell Rescue. Unknown status NCT02006225 Phase 4 Plerixafor
3 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
4 Use of Integrated PET/MR to Evaluate Clinical Staging and Monitor Treatment Response of Neoadjuvant Chemotherapy for Breast Cancer Patients: A Pilot Study Unknown status NCT02766530 Phase 4
5 Prospective Trial of Intravenous Levetiracetam in Patients With Primary Brain Tumors and at Least One Symptomatic Seizure Who Undergo Biopsy or Cytoreductive Surgery (HELLO-study) Completed NCT00571155 Phase 4 levetiracetam
6 Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
7 Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
8 A Prospective, Randomized Trial Comparing Surgery Versus Radiosurgery for the Treatment of Metastatic Brain Tumors Completed NCT00075166 Phase 4
9 Sugammadex Given for the Reversal of Deep Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants: A Retrospective Study Completed NCT02708056 Phase 4 Sugammadex
10 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
11 A Randomized, Open Label, Two-way Crossover, Single Dose Bioequivalence Study Comparing Dralitem® Capsules to the Reference Drug Temodal® Capsules in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
12 Influence of Vasopressors on Brain Oxygenation and Microcirculation in Anesthetized Patients With Cerebral Tumors Completed NCT02713087 Phase 4 Ephedrine;Phenylephrine
13 Phase IV, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare 0.10 Mmol/kg of MultiHance With 0.10 Omniscan in Magnetic Resonance Imaging (MRI) of the Brain Completed NCT00323102 Phase 4 Multihance
14 Effective and Safe Morphine Dose for Patient Controlled Anesthesia in Supratentorial Craniotomies Completed NCT04313374 Phase 4 Morphine PCA 1 mg;Morphine PCA 0,5 mg;Placebo
15 A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
16 A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
17 Phase IV, Double-blind, Multi-center, Randomized, Crossover Study to Compare 0.1 mmol/kg of Prohance® With 0.1 mmol/kg of Gadovist®/Gadavistâ„¢ in Magnetic Resonance Imaging (MRI) of the Brain (TRUTH) Completed NCT01613417 Phase 4 gadoteridol;gadobutrol
18 The Effect of Pre-incisional Anterior Scalp Block on Intraoperative Opioid Consumption in Adult Patients Undergoing Elective Craniotomy to Remove Tumor: A Prospective Randomized Controlled Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
19 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
20 The Effect of Dexmedetomidine as an Adjuvant to General Anesthesia on Intelligence Development in Pediatric Patients Undergoing Craniotomy: a Randomized, Double-blind and Placebo-controlled Pilot Trial Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
21 The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block: A Randomized Controlled Trial Completed NCT02558569 Phase 4 Levobupivacaine
22 Validation and Verification of 3 Dimensional Laparoscopic System in Laparoscopic Distal Pancreatectomy & Splenectomy Completed NCT02757690 Phase 4
23 The Effect of Intravenous Single Dose of Magnesium Sulphate on Attenuation of Hemodynamic Pressor Response After Myfield's Clamp Application During Craniotomies Completed NCT03318471 Phase 4 MgSo4;0.9% NaCl
24 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
25 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
26 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
27 A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial Recruiting NCT02334722 Phase 4 Levetiracetam extended release
28 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
29 Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome of Patients Undergoing Brain Tumor Exclusion Recruiting NCT04266665 Phase 4 Dexmedetomidine
30 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
31 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
32 Effects of Pre-emptive Scalp Infiltration With Ketorolac and Ropivacaine for Postoperative Pain Relief After Elective Supratentorial Craniotomy (PAINLESS) Not yet recruiting NCT04141319 Phase 4 Ketorolac;Ropivacaine;Epinephrine
33 Phase IV GliaSite® Radiation Therapy System Registry Protocol for the Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
34 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4 Conivaptan
35 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
36 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
37 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
38 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
39 Role of 3-D Navigable Ultrasound in Resection of Intra-axial Brain Tumors - A Randomized Controlled Study Unknown status NCT02150564 Phase 3
40 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
41 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
42 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
43 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
44 Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma Unknown status NCT01290939 Phase 3 lomustine
45 Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients With and Without Traumatic Brain Injury. Unknown status NCT03285165 Phase 2, Phase 3 0.2-0.7 mcg/kg/h dexmedetomedine infusion.;10-70 mcg/kg/h propofol infusion.
46 Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures Unknown status NCT02563288 Phase 3 Esmolol;Dexmedetomidine
47 Phase 3 Study of Stereotactic Radiotherapy of the Postoperative Resection Cavity Versus Whole-Brain Irradiation After Surgical Resection of Single Brain Metastasis Unknown status NCT01535209 Phase 3
48 Gefitinib Alone or With Concomitant Whole Brain Radiotherapy for Patients Harboring an EGFR Mutation With Multiple Brain Metastases From Non-Small-cell Lung Cancer: a Phase II/III Randomized Controlled Trial Unknown status NCT02338011 Phase 2, Phase 3 Gefitinib
49 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Effective on Erlotinib or Gefitinib(RT1001) Unknown status NCT01158170 Phase 3 Erlotinib /Gefitinib
50 A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis Unknown status NCT02460068 Phase 3 Fotemustine;Fotemustine and Ipilimumab;Ipilimumab and nivolumab

Search NIH Clinical Center for Brain Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine
Etoposide
etoposide phosphate
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Lomustine
Mifepristone
peginterferon alfa-2a
peginterferon alfa-2b
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Cochrane evidence based reviews: brain neoplasms

Sources

Genetic Tests for Brain Cancer

About this section

Genetic tests related to Brain Cancer:

# Genetic test Affiliating Genes
1 Malignant Neoplasm of Brain 29
Sources

Anatomical Context for Brain Cancer

About this section

MalaCards organs/tissues related to Brain Cancer:

40
Brain, Breast, Lung, T Cells, Testes, Endothelial, Bone
Sources

Publications for Brain Cancer

About this section

Articles related to Brain Cancer:

(show top 50) (show all 3805)
# Title Authors PMID Year
1
Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography. 42
32443328 2020
2
The Day My Gut Feeling Led Me Astray. 42
32402159 2020
3
Imaging of Neuronal and Mixed Glioneuronal Tumors. 42
32217897 2020
4
Survey of MicroRNA expression in pediatric brain tumors. 46
21157891 2011
5
FasL gene knock-down therapy enhances the antiglioma immune response. 61 54
20406899 2010
6
Mig-6 controls EGFR trafficking and suppresses gliomagenesis. 61 54
20351267 2010
7
MRI-coupled fluorescence tomography quantifies EGFR activity in brain tumors. 54 61
20152724 2010
8
CMDS: a population-based method for identifying recurrent DNA copy number aberrations in cancer from high-resolution data. 54 61
20031968 2010
9
A review of studies on targeting interleukin 4 receptor for central nervous system malignancy. 54 61
19689300 2009
10
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. 54 61
19333229 2009
11
Therapeutic targeting of g-protein coupled receptor-mediated epidermal growth factor receptor transactivation in human glioma brain tumors. 54 61
18991757 2008
12
Somatic alterations in brain tumors. 61 54
18575738 2008
13
Gene expression profiling of metastatic brain cancer. 54 61
17611651 2007
14
Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. 61 54
17483310 2007
15
Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. 54 61
17679463 2007
16
Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. 54 61
17440072 2007
17
Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. 54 61
17172420 2006
18
New roles for galectins in brain tumors--from prognostic markers to therapeutic targets. 54 61
15912884 2005
19
RNA interference and nonviral targeted gene therapy of experimental brain cancer. 54 61
15717065 2005
20
Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. 54 61
15173073 2004
21
Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors. 61 54
12540498 2003
22
Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly (lactide-co-glycolide) microsphere formulations for potential combination therapy in cancer. 61 54
11839444 2002
23
Ethnicity delineates different genetic pathways in malignant glioma. 54 61
11358811 2001
24
Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. 54 61
8700129 1996
25
High-affinity mutant Interleukin-13 targeted CAR T cells enhance delivery of clickable biodegradable fluorescent nanoparticles to glioblastoma. 61
32405577 2020
26
Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma. 61
32320860 2020
27
Survival among patients with glioma in the US Military Health System: A comparison with patients in the Surveillance, Epidemiology, and End Results program. 61
32286688 2020
28
Homotypic targeting and drug delivery in glioblastoma cells through cell membrane-coated boron nitride nanotubes. 61
32394995 2020
29
LINC01198 facilitates gliomagenesis through activating PI3K/AKT pathway. 61
32378450 2020
30
Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy. 61
32335153 2020
31
Fertility in female cancer survivors: a systematic review and meta-analysis. 61
32456969 2020
32
Exposure to lead increases the risk of meningioma and brain cancer: A meta-analysis. 61
32146339 2020
33
Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma. 61
32200460 2020
34
Pathway analysis of glutamate-mediated, calcium-related signaling in glioma progression. 61
31954716 2020
35
AFM Imaging of Protein Aggregation in Studying the Impact of Knotted Electromagnetic Field on A Peroxidase. 61
32488177 2020
36
A dosimetric comparison of flattening filter free and conventional VMAT treatments for some common cancer sites. 61
32409856 2020
37
Defining Treatment-Related Adverse Effects in Patients with Glioma: Distinctive Features of Pseudoprogression and Treatment-Induced Necrosis. 61
32488924 2020
38
'Prodrug-like' acetylmannosamine modified liposomes loaded with arsenic trioxide for the treatment of orthotopic glioma in mice. 61
32534027 2020
39
Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma. 61
32554237 2020
40
The Longitudinal Imaging Tracker (BrICS-LIT):A Cloud Platform for Monitoring Treatment Response in Glioblastoma Patients. 61
32548285 2020
41
Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases. 61
32559056 2020
42
Use of a Luciferase-Expressing Orthotopic Rat Brain Tumor Model to Optimize a Targeted Irradiation Strategy for Efficacy Testing with Temozolomide. 61
32549357 2020
43
lncRNA LINC00665 Stabilized by TAF15 Impeded the Malignant Biological Behaviors of Glioma Cells via STAU1-Mediated mRNA Degradation. 61
32464546 2020
44
Targeted Brain Tumor Radiotherapy Using an Auger Emitter. 61
32066626 2020
45
Transmembrane protein 45A regulates the proliferation, migration, and invasion of glioma cells through nuclear factor kappa-B. 61
32568829 2020
46
A TfR-Binding Cystine-Dense Peptide Promotes Blood-Brain Barrier Penetration of Bioactive Molecules. 61
32304700 2020
47
Coagulation factor 2 thrombin receptor promotes malignancy in glioma under SOX2 regulation. 61
32507767 2020
48
The Prognostic Value of EMT in Glioma and its Role in the Glioma Immune Microenvironment. 61
32495005 2020
49
Ras Suppressor-1 (RSU1) in Cancer Cell Metastasis: A Tale of a Tumor Suppressor. 61
32517326 2020
50
TP3, an antimicrobial peptide, inhibits infiltration and motility of glioblastoma cells via modulating the tumor microenvironment. 61
32266797 2020
Sources

Variations for Brain Cancer

About this section

ClinVar genetic disease variations for Brain Cancer:

6 (show top 50) (show all 237) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_001126112.2(TP53):c.832C>A (p.Pro278Thr)SNV Likely pathogenic,drug response 376643 rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_001126112.2(TP53):c.523C>G (p.Arg175Gly)SNV Pathogenic 376649 rs138729528 17:7578407-7578407 17:7675089-7675089
3 TP53 NM_001126112.2(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
4 TP53 NM_001126112.2(TP53):c.722C>A (p.Ser241Tyr)SNV Pathogenic 376663 rs28934573 17:7577559-7577559 17:7674241-7674241
5 TP53 NM_001126112.2(TP53):c.730G>A (p.Gly244Ser)SNV Pathogenic 376600 rs1057519989 17:7577551-7577551 17:7674233-7674233
6 TP53 NM_001126112.2(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
7 TP53 NM_001126112.2(TP53):c.578A>C (p.His193Pro)SNV Pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
8 TP53 NM_001126112.2(TP53):c.517G>T (p.Val173Leu)SNV Pathogenic 376668 rs876660754 17:7578413-7578413 17:7675095-7675095
9 PTEN NM_000314.7(PTEN):c.388C>T (p.Arg130Ter)SNV Pathogenic 7819 rs121909224 10:89692904-89692904 10:87933147-87933147
10 PTEN NM_000314.8(PTEN):c.1003C>T (p.Arg335Ter)SNV Pathogenic 7833 rs121909231 10:89720852-89720852 10:87961095-87961095
11 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
12 TP53 NM_001126112.2(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
13 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
14 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
15 TP53 NM_001126112.2(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
16 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
17 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
18 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
19 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
20 BRAF NM_001374258.1(BRAF):c.1919T>A (p.Val640Glu)SNV Pathogenic,drug response 13961 rs113488022 7:140453136-140453136 7:140753336-140753336
21 BRAF NM_001374258.1(BRAF):c.1901A>G (p.Asp634Gly)SNV Pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354
22 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg)SNV Pathogenic 45466 rs397517201 3:178936095-178936095 3:179218307-179218307
23 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
24 TP53 NM_001126112.2(TP53):c.422G>A (p.Cys141Tyr)SNV Pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
25 TP53 NM_001126112.2(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
26 TP53 NM_001126112.2(TP53):c.488A>G (p.Tyr163Cys)SNV Pathogenic 127814 rs148924904 17:7578442-7578442 17:7675124-7675124
27 TP53 NM_001126112.2(TP53):c.706T>G (p.Tyr236Asp)SNV Pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
28 IDH1 NM_001282386.1(IDH1):c.395G>A (p.Arg132His)SNV Pathogenic 156444 rs121913500 2:209113112-209113112 2:208248388-208248388
29 TP53 NM_001126112.2(TP53):c.856G>A (p.Glu286Lys)SNV Pathogenic 183752 rs786201059 17:7577082-7577082 17:7673764-7673764
30 TP53 NM_001126112.2(TP53):c.374C>A (p.Thr125Lys)SNV Pathogenic 216465 rs786201057 17:7579313-7579313 17:7675995-7675995
31 TP53 NM_001126112.2(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
32 TP53 NM_001126112.2(TP53):c.517G>A (p.Val173Met)SNV Pathogenic 233951 rs876660754 17:7578413-7578413 17:7675095-7675095
33 TP53 NM_001126112.2(TP53):c.743G>C (p.Arg248Pro)SNV Pathogenic 237954 rs11540652 17:7577538-7577538 17:7674220-7674220
34 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
35 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His)SNV Pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
36 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys)SNV Pathogenic 376470 rs1057519925 3:178928079-178928079 3:179210291-179210291
37 PTEN NM_000314.7(PTEN):c.517C>T (p.Arg173Cys)SNV Pathogenic 189500 rs121913293 10:89711899-89711899 10:87952142-87952142
38 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
39 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
40 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
41 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
42 TP53 NM_001126112.2(TP53):c.713G>T (p.Cys238Phe)SNV Pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
43 TP53 NM_001126112.2(TP53):c.713G>C (p.Cys238Ser)SNV Pathogenic 376575 rs730882005 17:7577568-7577568 17:7674250-7674250
44 TP53 NM_001126112.2(TP53):c.712T>C (p.Cys238Arg)SNV Pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
45 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly)SNV Pathogenic/Likely pathogenic 13656 rs121913274 3:178936092-178936092 3:179218304-179218304
46 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu)SNV Pathogenic/Likely pathogenic 375874 rs11554290 1:115256529-115256529 1:114713908-114713908
47 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln)SNV Pathogenic/Likely pathogenic 376244 rs121913273 3:178936082-178936082 3:179218294-179218294
48 TP53 NM_001126112.2(TP53):c.731G>A (p.Gly244Asp)SNV Pathogenic/Likely pathogenic 372785 rs985033810 17:7577550-7577550 17:7674232-7674232
49 IDH1 NM_001282386.1(IDH1):c.395G>T (p.Arg132Leu)SNV Pathogenic/Likely pathogenic 375889 rs121913500 2:209113112-209113112 2:208248388-208248388
50 PTEN NM_000314.8(PTEN):c.518G>A (p.Arg173His)SNV Pathogenic/Likely pathogenic 376032 rs121913294 10:89711900-89711900 10:87952143-87952143

Cosmic variations for Brain Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM151343377 central nervous system,brain,primitive neuroectodermal tumour-medulloblastoma,classic c.77C>G p.S26C 3:41224610-41224610 4

Copy number variations for Brain Cancer from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 112045 17 37800000 41900000 Gain Brain cancer
2 179187 8 123863081 124055936 Deletion RAF Brain cancer
3 205638 6 130400000 131300000 Deletion Brain cancer
4 233881 8 128747764 129113498 Amplification MYC Brain cancer
5 234173 8 131500000 139900000 Amplification KHDRBS3 Brain cancer
6 254105 9 51800000 140273252 Deletion Brain cancer
Sources

Expression for Brain Cancer

About this section
Search GEO for disease gene expression data for Brain Cancer.
Sources

Pathways for Brain Cancer

About this section

Pathways related to Brain Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
TGF-Beta Pathway 63
Show member pathways
 13.58 TP53 PTPN11 PIK3CA NRAS EPHB2 EGFR
2
Cytokine Signaling in Immune system 65
Show member pathways
 13.4 TP53 PTPN11 PIK3CA NRAS EGFR EGF
3
GAB1 signalosome 65
Show member pathways
 13.15 TP53 PTPN11 PTEN PIK3CA EGFR EGF
4
Phospholipase-C Pathway 63
Show member pathways
 13.11 TP53 PTEN NRAS EGFR EGF BRAF
5
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.09 TP53 PIK3CA NRAS EGFR EGF BRAF
6
PI3K-Akt signaling pathway 36
Show member pathways
 13.03 TP53 PTEN PIK3CA NRAS EGFR EGF
7
Focal Adhesion 36 1
Show member pathways
 12.94 PTEN PIK3CA NRAS EGFR EGF BRAF
8
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 12.93 PTPN11 PTEN PIK3CA NRAS EGFR EGF
9
Endometrial cancer 36
Show member pathways
 12.84 TP53 PTPN11 PTEN PIK3CA NRAS EGFR
10
MAPK signaling pathway 36 1
12.8 TP53 NRAS EGFR EGF BRAF
11
Pathways in cancer 36
12.78 TP53 PTEN PIK3CA NRAS EGFR EGF
12
Ras signaling pathway 36
Show member pathways
 12.76 PTPN11 PIK3CA NRAS EGFR EGF BRAF
13
Development HGF signaling pathway 22
Show member pathways
 12.74 TP53 PTPN11 PTEN PIK3CA NRAS BRAF
14
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.73 TP53 PTPN11 PTEN PIK3CA NRAS EGFR
15
4-1BB Pathway 63
Show member pathways
 12.71 TP53 NRAS EGFR EGF BRAF
16
Regulation of actin cytoskeleton 36 1
12.68 PIK3CA NRAS EGFR EGF BRAF
17
Gastric cancer 36
Show member pathways
 12.64 TP53 SMARCB1 PTEN PIK3CA NRAS EGFR
18
Immune response IL-23 signaling pathway 22
Show member pathways
 12.63 TP53 PTPN11 PIK3CA NRAS EGFR
19
T cell receptor signaling pathway 36
Show member pathways
 12.6 PTPN11 PTEN PIK3CA NRAS EGFR EGF
20
MicroRNAs in cancer 36
12.56 TP53 PTEN PIK3CA NRAS MIR25 EGFR
21
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.53 TP53 PTEN PIK3CA NRAS EGFR BRAF
22
VEGF Signaling 66
Show member pathways
 12.52 TP53 PTEN PIK3CA NRAS EGFR EGF
23
JAK-STAT signaling pathway 36
Show member pathways
 12.5 PTPN11 PIK3CA NRAS EGFR EGF
24
B Cell Receptor Signaling Pathway (sino) 66
Show member pathways
 12.48 PTPN11 PTEN PIK3CA NRAS
25
Apoptosis Pathway 70
Show member pathways
 12.47 TP53 PIK3CA NRAS EGFR
26
Glioma 36
Show member pathways
 12.46 TP53 PTEN PIK3CA NRAS EGFR EGF
27
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 12.44 PTPN11 PTEN PIK3CA NRAS BRAF
28
Phospholipase D signaling pathway 36
Show member pathways
 12.44 PTPN11 PIK3CA NRAS EGFR EGF
29
Development IGF-1 receptor signaling 22
Show member pathways
 12.43 TP53 PTPN11 PTEN PIK3CA
30